Corporate Presentation

TSX-V: CZO
Corporate Presentation
1
Forward Looking Statements
This presentation contains forward-looking statements. Various
factors could cause actual results to differ materially from those
projected in forward-looking statements, including those predicting the
timing of product development and launches. Although the company
believes that the forward-looking statements contained herein are
reasonable, it can give no assurance that the Company’s expectations
are correct.
All forward-looking statements are expressly qualified by this
Cautionary Statement.
2
Overview
• Canadian leader in botanical actives innovation and
bioprocessing
o Proprietary plant extraction based manufacturing process
o Active ingredients for health care and cosmetic industries
• Two active ingredients currently used in household name
products - Cosmetics & Personal Care
o Beta Glucan
o Avenanthramides
• De-risked business model and robust growth strategy
support potential for significant market expansion and
revenue generation
• Near-term potential to expand into nutraceutical, OTC and
Pharma markets
3
Ceapro’s Core Expertise
The identification, extraction
and purification of active
compounds from natural
sources…
…which allows us to create
innovative ingredients for the
personal and healthcare
industries
…We are a Green Company!
4
Proprietary plant extraction based
manufacturing
Beta Glucan
Avenanthramides
Lupinus angustifolia
And
Avena sativa
5
Unique Bioprocessing Expertise
•
Ability to isolate and purify
specific molecules from a wide
range of botanical sources
•
Prototype extracts are then
prepared for bio-screening or in
vivo testing
•
Unique drying (heat-free) technology for sensitive compounds
•
Commercialized unique bio-actives from several botanical sources
•
Ability to take concept to commercialization in a relatively short
period of time
6
New & Innovative Technologies:
“Pressurized Gas Expanded (PGX) Liquid –Spray Drying”
7
CNC before and after PGX drying
• Production of biomaterials from different industries
0.5 g CNC
Spray Dried
0.5 g CNC
PGX Dried
CNC AEROGEL
Density : 0.006 g/cm3
Application of PGX-CNC
• Applications of PGX-CNC
•
•
•
•
•
Wound healing, scaffolds
Drug delivery
Absorbants
Composite-Plastics
Paints
• PGX processing allows processing of high value
biopolymers:
•
•
•
•
Beta Glucan
Chitosan
Gum Arabic
CNC
Market Sectors (Current & Future)
Cosmetics & Personal Care
• Anti-Inflammation
• Anti-Ageing
Nutraceuticals/Functional Foods
• Metabolic Diseases
Pharma/OTC(Botanic Drugs)
• Wound Healing
• Metabolic Diseases
10
Cosmetics - From Field to Formulation
Field
Identify
Research
Discover
Manufacturing
Develop
Consumer
Provide
Unique
Plants
Novel
Functional
Actives
Innovative
Processes
Innovative
Products
11
Beta Glucan and Avenanthramides in
Multiple Household Products
•
Aveeno
• Coppertone
•
Jergens
• Dove
•
Lubriderm
• Burt’s Bees
•
3M –Nexcare
• The Body Shop
•
KY Products
• Philosophy
•
Neutrogena
• ROC
12
A Hidden Gem….
13
Ceapro – Our Value Drivers
Beta glucan
Avenanthramides
14
Beta Glucan
•
Beta glucan is a soluble fibre found in the call walls of oat
kernels
•
Acts as a natural moisture barrier and film-forming agent
•
Relieves and alleviates dry and itchy skin by replenishing
and protecting the skin’s moisture barrier
•
Provides hydration against the drying effects of the sun
•
Smoothens wrinkles, reducing the visible signs of ageing
15
Beta Glucan in Cosmeceuticals
•
Ceapro was the first to
demonstrate that high
molecular weight beta
glucan can penetrate human
skin.
•
Dermatology applications
range from anti-ageing to
wound healing.
•
New highly purified beta
glucan powder successfully
developed to address new
market demands/trends.
16
Natural Skin Restructuring Agent
•
Proven to effectively reduces
fine lines & wrinkles
•
Forms a natural barrier
protecting skin
•
Wound healing agent – films
or gels
•
Sustained release of active
agents requiring enhanced
percutaneous transportation
17
Avenanthramides
•
Antihistamine and antiinflammatory properties
•
Potential benefits in the
control of inflammationbased diseases
18
Avenanthramides Clinically Proven in Cosmeceuticals
Significant improvements in
erythema symptoms associated
in subjects with mild to
moderate atopic dermatitis
• 40% improvement in itch
perception after 1 week
• 62% of patients showed an
improvement in their skin
condition
Subjects with atopy
• 89% of subjects saw
significant improvement in
itch after 1 week
• Continued improvement
after 4 weeks
19
Our Value Drivers – Advanced Skin Care
Skin inflammation is a complex physiological process
Beta glucan
•
•
•
•
Beta glucan
Accelerates tissue healing
Deep hydrating agent
Improves elasticity
Natural film protective barrier
Avenanthramides
• Relief from itching (Pruritus)
• Reduces inflammation and swelling
Avenanthramides
• Reduces redness (Erythema)
20
Robust Growth Strategy
Cosmeceuticals
•
•
•
•
•
Generate scientific data to support current product indications
Pursue new indications for current product portfolio from research programs
Develop new products in accordance with needs expressed by customers
Improve manufacturing technologies
Look for ability to develop co-products
Nutraceuticals
• Produce 2nd generations of current products (higher concentrations,
powder versions, etc)
• Capture bigger margins
Pharmaceuticals
• Produce 3rd generations of current products (higher concentrations,
powder versions, etc)
• Conduct formulation work and assess potential for pharmaceutical
development
21
Beta Glucan in Nutraceuticals and
Pharmaceuticals
• Potential reduction of cardiovascular and heart diseases risk
o Acts to decrease LDL and total cholesterol
• Proprietary beta glucan drug-delivery platform
o Shown to effectively penetrate into the skin, into the deep
layers as well as into the skin cells
o Uses ranging from wound care and therapy, to skin care
treatments that reduce the signs of aging
22
Avenanthramides in Nutraceuticals and
Pharmaceuticals
• Avenanthramides shown to
attenuate exercise-induced
inflammation in animal studies
• Human clinical studies showed that
dietary avenanthramides
supplements significantly reduced
inflammation biomarkers in an
elderly population
• New process technology licensed
from Agriculture and Agri-Food
Canada (AAFC)
23
Value Drivers
Cosmeceuticals - Current and new indications-Base Business
Nutraceuticals - New product development-Near Term Catalyst
Pharmaceuticals - New products, new partnership discussions
Manufacturing Innovation - New processes, higher output, lower cost
24
New Bio-processing Facility
•
R&D
•
Pilot Scale Capability
•
Commercial Production
New 21,000 sq. ft. GMP Bio-processing Extraction
Facility in Edmonton, Alberta
25
Value-Driving Milestones
2015 - H1
2015 - H2
2016 - H1
2016 - H2
New Manufacturing Facility
Commercial scale-up of dry powder
technology platform
Ceapro in Nutraceuticals and Pharmaceuticals
Beta Glucan preclinical studies
Beta Glucan Pilot Phase
Avenanthramides Phase ½
26
Financial Profile - TSX-V: CZO
TSX-V: CZO
Stock Ticker
$43,000,000
Market capitalization as of January 2, 2015
61,420,000
Common shares outstanding
$6,831,000
Total sales for the nine-month period ending
September 2014
$4,000,000
Total amount of grant-based-funding raised to date
27
Financial Performance 2009-2013
8000
6000
4000
2000
0
2009
2010
2011
2012
2013
-2000
Revenue
Income (loss) from Operations ($000)
28
Financial Performance
First 9 months 2014 vs 2013 (in 000’s)
$8 000
$7 000
$6 000
$5 000
$4 000
$3 000
$2 000
$1 000
$0
2013
Revenue
2014
Net Income
29
Recent Positive Momentum
12/4 - Research Grant
from Alberta Innovates
Bio Solutions
$0,80
$0,70
11/20 - Appoints
William W. Li, M.D. to
Board of Directors
Price
$0,60
11/14 - Third Quarter
2014 Financial Results
$0,50
$0,40
12/18 - Ceapro Enters
into Financing
Agreement
7/30 - Second Quarter
2014 Financial Results
$0,30
11/26 - Research
Scientist Honored with
Scientific Achievement
$0,20
$0,10
$0,00
7-1-10
7/1/14
10/3 - Change of
Chairman of the Board
7-31-10
7/31/14
8-30-10
8/30/14
9-29-10
9/29/14
10-29-10
10/29/14
11-28-10
11/28/14
12-28-104
12/28/14
Date
30
Ceapro is Poised for an Exciting 2015
A Solid Company!







Profitable
Highly-experienced, results-driven team
Operational efficiency
Solid innovative science/IP
Commercially accepted products
Expanded Marketing/Sales territories
Strong development Pipeline for long-term
sustainable growth
31
Thank you!
www.ceapro.com
32